Author

A. Armandi

h-index 28 View on Semantic Scholar

We have 4 of 175 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review

Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohort

N. Pérez-Díaz-Del-Campo, G. Castelnuovo, Arianna Ferro et al. · 1 citation

Sep 2026

Personalised prediction of the individual risk of liver-related events in MASLD using the dynamics of non-invasive tests.

BACKGROUND AND AIMS The evolution of non-invasive tests of liver fibrosis during follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains difficult to interpret in clinical practice. We aimed to translate the dynamics of non-invasive tests into a personalized prediction of liv...

C. Moreau, M. Roux, J. Riou et al. · Clinical Gastroenterology an... · 0 citations

METABOLIC MECHANISMS OF LIVER FIBROSIS PROGRESSION AND NON-INVASIVE BIOMARKERS OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE

A. Armandi, E. Bugianesi, Benedetta Bussolati · 0 citations

Open access Aug 2026

MBOAT7 rs641738 TT genotype is associated with poorer survival in MASLD-related hepatocellular carcinoma

MBOAT7 rs641738 genotype was associated with poorer OS in patients with MASLD-related HCC, but between-cohort differences limit etiological interpretation.

M. Guariglia, G. Caviglia, Silvia Gaia et al. · Frontiers in Oncology · 0 citations